Evolutionary biology of high-risk multiple myeloma

Nature Reviews Cancer 17, 543 (2017). doi:10.1038/nrc.2017.63 Authors: Charlotte Pawlyn & Gareth J. Morgan The outcomes for the majority of patients with myeloma have improved over recent decades, driven by treatment advances. However, there is a subset of patients considered to have high-risk disease who have not benefited. Understanding how high-risk disease evolves from more therapeutically tractable stages is
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research